Benzinga · Aug 12, 2026
TD Cowen Maintains Hold on DarioHealth, Lowers Price Target to $8
TD Cowen analyst Charles Rhyee maintains DarioHealth (NASDAQ:DRIO) with a Hold and lowers the price target from $11 to $8.
DR
NASDAQ · DRIO
DarioHealth Corp.
Healthcare · Medical - Diagnostics & Research
$7.59
Up+$0.26 (+3.48%)
Updated Aug 16, 2026, 6:54 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 86.71M
- P/E ratio
- -51.67
- Dividend yield
- 0.00%
- 52-week range
- $5.84 – $17.74
- Volume
- 5.32K
- Avg. volume
- 68.53K
Price performance
DRIO price history
1M range · 20 trading sessions · Daily adjusted prices
DRIO closed at $7.59 after 20 trading sessions, up 12.04% for the selected period.
- Last close
- $7.59
- Period change
- +12.04%
- Period low
- $6.77
- Period high
- $7.90
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $7.24 | $7.915 | $7.24 | $7.585 | 5.32K |
| Aug 13, 2026 | $7.72 | $7.94 | $7.21 | $7.33 | 9.36K |
| Aug 12, 2026 | $7.67 | $7.7827 | $7.165 | $7.48 | 10.2K |
| Aug 11, 2026 | $7.34 | $8.03 | $6.75 | $7.67 | 54.98K |
| Aug 10, 2026 | $7.415 | $7.89 | $6.90 | $7.66 | 24.34K |
| Aug 7, 2026 | $7.335 | $8.20 | $7.30 | $7.30 | 29.57K |
| Aug 6, 2026 | $7.67 | $7.88 | $7.40 | $7.748 | 3.96K |
| Aug 5, 2026 | $6.975 | $7.66 | $6.695 | $7.66 | 17.08K |
| Aug 4, 2026 | $7.30 | $7.71 | $6.19 | $6.87 | 164.68K |
| Aug 3, 2026 | $7.22 | $7.52 | $6.83 | $7.10 | 9.84K |
| Jul 31, 2026 | $7.50 | $7.50 | $7.01 | $7.27 | 7.37K |
| Jul 30, 2026 | $7.50 | $7.53 | $6.902 | $7.20 | 16.2K |
| Jul 29, 2026 | $7.78 | $7.78 | $7.02 | $7.10 | 12.09K |
| Jul 28, 2026 | $7.255 | $7.89 | $7.01 | $7.495 | 8.22K |
| Jul 27, 2026 | $7.48 | $8.1481 | $7.00 | $7.47 | 8.71K |
| Jul 24, 2026 | $7.50 | $7.90 | $7.31 | $7.79 | 3.79K |
| Jul 23, 2026 | $7.74 | $8.00 | $6.80 | $7.47 | 11.46K |
| Jul 22, 2026 | $7.00 | $7.90 | $6.855 | $7.90 | 181.89K |
| Jul 21, 2026 | $7.00 | $7.00 | $6.6794 | $7.00 | 10.96K |
| Jul 20, 2026 | $6.75 | $7.10 | $6.07 | $6.77 | 12.77K |
Latest DRIO news
The latest Smart Investors Daily articles mentioning DRIO.
Stock researchCompany · Overview
DRIO research
Overview
Company profile and research snapshot.
Company profile
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $16.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | TD Cowen | Hold | — |
| Mar 20, 2026 | Stifel | Buy | — |
| May 19, 2025 | Litchfield Hills | Buy | — |
| Mar 11, 2025 | Stifel | Buy | — |
| Apr 1, 2024 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 11, 2026
DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript
DarioHealth Corp. (DRIO) Q2 2026 Earnings Call August 11, 2026 8:30 AM EDTCompany ParticipantsZoe Harrison - VP of Accounting & Corporate...
Benzinga · Aug 11, 2026
DarioHealth Q2 Adj. EPS $(0.72) Beats $(1.22) Estimate, Sales $5.177M Miss $5.923M Estimate
DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(1.22) by 40.98 percent. This is a 82.44 percent increase over losses of $(4.10) per share from the
Benzinga · Jul 30, 2026
DarioHealth Launches GLP-1 Program, With Commercial Availability Expected Fall 2026, With Revenue Contribution From Late 2026 And Ramping Through 2027
First commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario's chronic care platformLaunch addresses
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
